Search results
Showing 3001 to 3015 of 7690 results
This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04
This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84
How NICE uses cookies and how you can manage them.
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Find out more about the medical technologies advisory committee members by reading their biographies. Dr Jacob Brown (chair) Biography Jacob
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Information about providers of medical and healthcare related content under the NICE Electronic and Print Content Framework Agreement
Where you can find more information about how we operate
We are evolving to make sure we’re meeting the changing needs of the health and care system
Our board sets out our strategic priorities and policies.
What we do NICE has a key role in the evaluation of and access to new and innovative medicines and treatments for the health system, playing an...
Resources to help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
This indicator covers the percentage of children who have reached 5 years old in the preceding 12 months, who have received a reinforcing dose of DTaP/IPV and at least 2 doses of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM199